Journal of Istanbul Faculty of Medicine

SUBMITINFORMATION
EnglishTürkçe

Review


DOI :https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91   IUP :https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91    Full Text (PDF)

Polycythemia vera: Update on pathogenesis, diagnosis and management.

İpek Yönal Hindilerden, Fatma Deniz Sargın

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell mass and usually overproduction of granulocytes and platelets and increased spleen size. JAK2V617F mutation is present in more than 95% of PV patients. Bone marrow examination reveals excessive proliferation of erythroid, myeloid, and megakaryocytic elements. The prognosis of PV depends on the severity of the complications occurring during the clinical course. Thrombotic complications are the main cause of morbidity and mortality in PV. Survival is affected whether appropriate therapy is applied during the erythrocytotic phase of the disease. Uncontrolled erythrocytosis poses very high risk for development of thrombosis. Some studies suggest that PV patients have a normal or near-normal life-expectancy. Most studies, however, report excess mortality caused by thrombotic complications and acute leukemia transformation during course of PV. This review aims to highlight the pathogenesis, diagnosis and current management in PV.

Keywords: Acute leukemia transformation;, Myeloproliferative neoplasm, Polycythemia vera, Thrombotic complications
DOI :https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91   IUP :https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91    Full Text (PDF)

POLİSİTEMİA VERA: PATOGENEZ, TEŞHİS VE TEDAVİDE GÜNCEL BİLGİLER

İpek Yönal Hindilerden, Fatma Deniz Sargın

Polisitemia vera (PV), eritrosit kitlesinde mutlak artış ile karakterize, sıklıkla granülosit ve trombositlerin aşırı üretiminin ve splenomegalinin eşlik ettiği bir miyeloproliferatif neoplazidir. JAK2V617F mutasyonu, PV tanılı olguların %95’inden fazlasında görülmektedir. Kemik iliği incelemesinde eritroid, miyeloid ve megakaryositik seride proliferasyon görülür. PV’nın prognozu, klinik seyir sırasında ortaya çıkan komplikasyonların ciddiyetine bağlıdır. PV’da morbidite ve mortalitenin ana nedeni trombotik komplikasyonlardır. Yaşam, hastalığın pletorik fazında uygun tedavinin başlanıp başlanmamasından etkilenmektedir. Kontrol edilemeyen eritrositoz varlığında tromboz riski belirgin şekilde artış gösterir. Bazı çalışmalarda PV’nın normal veya normale yakın yaşam süresi ile ilişkisi gösterilmiştir. Fakat, birçok çalışmada PV’da trombotik komplikasyonlar ve akut lösemiye dönüşüm sonucunda artmış mortalite olduğu bildirilmiştir. Bu derlemenin amacı, PV tanılı olgularda patogenez, tanı yöntemleri ve güncel tedaviyi vurgulamaktır.

Keywords: Akut lösemiye dönüşüm, Miyeloproliferatif neoplazi, Polisitemia vera, Trombotik komplikasyonlar

PDF View

References

  • 1.Anger B, Haug U, Seidler R, Heimpel H.Polycythemia vera. A clinical study of 141 patients. Blut. 1989;59(6):493-500. google scholar
  • 2. Balan KK, Critchley M. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32--a 15 year review. Br J Radiol. 1997;70(839):1169-73. google scholar
  • 3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61. google scholar
  • 4. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-43. google scholar
  • 5. Buchanan JG, Ameratunga RV, Hawkins RC. Polycythemia vera and water-induced pruritus: evidence against mast cell involvement. Pathology. 1994;26(1):43-5. google scholar
  • 6. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 1993;82(6):1749-57. google scholar
  • 7. Bittencourt RI, Vassallo J, Chauffaille Mde L, Xavier SG, Pagnano KB, Nascimento AC, De Souza CA, Chiattone CS. Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2012;34(2):140-9. google scholar
  • 8. Camós M, Cervantes F, Montoto S, Hernández-Boluda JC, Villamor N, Montserrat E. Acute lymphoid leukemia following polycythemia vera. Leuk Lymphoma. 1999;32(3-4):395-8. google scholar
  • 9. Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098–100. google scholar
  • 10. Caramazza D, Caracciolo C, Barone R, Malato A, Saccullo G, Cigna V, Berretta S, Schinocca L, Quintini G, Abbadessa V, Di Raimondo F, Siragusa S. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol. 2009;88(10):967-71. google scholar
  • 11. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37(9):1016-21. google scholar
  • 12. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-14. google scholar
  • 13. Crisà E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M, Ferrero D. google scholar
  • A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691-9. google scholar
  • 14. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 2002;16(7):1207-12. Review. google scholar
  • 15. Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, Leone G, Marfisi R, Porreca E, Ruggeri M, Rutjes AW, Tognoni G, Vannucchi AM, Marchioli R; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249-59. google scholar
  • 16. 16. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007;109:5104–5111. google scholar
  • 17. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, Tefferi A. Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 2007;21:270–276. google scholar
  • 18. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(9):656-64. google scholar
  • 19. Gutman AB, Kupfer S, Sharney L, Weissmann B, Yu TF. On the biosynthesis of uric acid from glycine-N15 in primary and secondary polycythemia. Am J Med. 1956;21(6):901-17. google scholar
  • 20. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45. google scholar
  • 21. Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD, Glembotsky AC, Vassallu PS, Marta RF, Molinas FC. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol, 2006; 77: 210–216. google scholar
  • 22. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8. google scholar
  • 23. Johansson P, Kutti J, Andréasson B, Safai-Kutti S, Vilén L, Wedel H, Ridell B. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med. 2004;256(2):161-5. google scholar
  • 24. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162-8. google scholar
  • 25. Kalgaard OM, Seem E, Kvernebo K. Erythromelalgia: a clinical study of 87 cases. J Intern Med. 1997;242(3):191-7. google scholar
  • 26. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90. google scholar
  • 27. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-24. google scholar
  • 28. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-97. google scholar
  • 29. Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23(5):441-54. google scholar
  • 30. Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood. 1997;89(6):1862-9. google scholar
  • 31. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood. 1999;94(8):2555-61. google scholar
  • 32. Nand S, Messmore H, Fisher SG, Bird ML, Schulz W, Fisher RI. Leukemic transformation in polycythemia vera: analysis of risk factors. Am J Hematol. 1990;34(1):32-6. google scholar
  • 33. Parker RG. Occlusion of the hepatic veins in man. Medicine (Baltimore). 1959;38:369-402. google scholar
  • 34. Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88(1):13-8. google scholar
  • 35. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2(8102):1219-22. google scholar
  • 36. Perkins J, Israuels MC, Wilkinson JF. Polycythaemia vera: clincical studies on a series of 127 patients managed without radiation therapy. Q J Med. 1964;33:499-518. google scholar
  • 37. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol. 1997;34(1):51-4. google scholar
  • 38. Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med. 1974;290(24):1382. google scholar
  • 39. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-55. google scholar
  • 40. Rosenbaum DL, Murphy GW, Swisher SN. Hemodynamic studies of the portal circulation in myeloid metaplasia. Am J Med. 1966;41(3):360-8. google scholar
  • 41. Röder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29(6):694-702. google scholar
  • 42. Salem HH, Van der Weyden MB, Young IF, Wiley JS. Pruritus and severe iron deficiency in polycythaemia vera. Br Med J (Clin Res Ed). 1982;285(6335):91-2. google scholar
  • 43. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol. 1997;34(1):40-50. google scholar
  • 44. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ, Eaton DL. Role of c-mpl in early hematopoiesis. Blood. 1998;92(1):4-10. google scholar
  • 45. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-90. google scholar
  • 46. Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol. 1985;13(1):91-6. google scholar
  • 47. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97(4):863-6. google scholar
  • 48. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006;108:2173–2181. google scholar
  • 49. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005;42:206-220. google scholar
  • 50. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22(1):14-22. Comment in: Leukemia. 2008;22(11):2118-9. google scholar
  • 51. Towell BL, Levine SP. Massive hepatomegaly following splenectomy for myeloid metaplasia. Case report and review of the literature. Am J Med. 1987;82(2):371-5. google scholar
  • 52. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer. 1981;44(1):75-80. google scholar
  • 53. Ugo V, Marzac C, Teyssandier I, Larbret F, Lécluse Y, Debili N, Vainchenker W, Casadevall N. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol. 2004;32(2):179-87. google scholar
  • 54. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, Maillard JN, Pariente EA, Leporrier M, Rueff B, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985;103(3):329-34. google scholar
  • 55. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol. 1991;63(2):101-6. google scholar
  • 56. Westin J, Granerus G, Weinfeld A, Wetterquist H. Histamine metabolism in polycythaemia vera. Scand J Haematol. 1975;15(1):45-57. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Yönal Hindilerden, İ., & Sargın, F.D. (2015). Polycythemia vera: Update on pathogenesis, diagnosis and management.. Journal of Istanbul Faculty of Medicine, 78(3), 83-91. https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


AMA

Yönal Hindilerden İ, Sargın F D. Polycythemia vera: Update on pathogenesis, diagnosis and management.. Journal of Istanbul Faculty of Medicine. 2015;78(3):83-91. https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


ABNT

Yönal Hindilerden, İ.; Sargın, F.D. Polycythemia vera: Update on pathogenesis, diagnosis and management.. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 78, n. 3, p. 83-91, 2015.


Chicago: Author-Date Style

Yönal Hindilerden, İpek, and Fatma Deniz Sargın. 2015. “Polycythemia vera: Update on pathogenesis, diagnosis and management..” Journal of Istanbul Faculty of Medicine 78, no. 3: 83-91. https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


Chicago: Humanities Style

Yönal Hindilerden, İpek, and Fatma Deniz Sargın. “Polycythemia vera: Update on pathogenesis, diagnosis and management..” Journal of Istanbul Faculty of Medicine 78, no. 3 (May. 2025): 83-91. https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


Harvard: Australian Style

Yönal Hindilerden, İ & Sargın, FD 2015, 'Polycythemia vera: Update on pathogenesis, diagnosis and management.', Journal of Istanbul Faculty of Medicine, vol. 78, no. 3, pp. 83-91, viewed 22 May. 2025, https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


Harvard: Author-Date Style

Yönal Hindilerden, İ. and Sargın, F.D. (2015) ‘Polycythemia vera: Update on pathogenesis, diagnosis and management.’, Journal of Istanbul Faculty of Medicine, 78(3), pp. 83-91. https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91 (22 May. 2025).


MLA

Yönal Hindilerden, İpek, and Fatma Deniz Sargın. “Polycythemia vera: Update on pathogenesis, diagnosis and management..” Journal of Istanbul Faculty of Medicine, vol. 78, no. 3, 2015, pp. 83-91. [Database Container], https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


Vancouver

Yönal Hindilerden İ, Sargın FD. Polycythemia vera: Update on pathogenesis, diagnosis and management.. Journal of Istanbul Faculty of Medicine [Internet]. 22 May. 2025 [cited 22 May. 2025];78(3):83-91. Available from: https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91 doi: https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91


ISNAD

Yönal Hindilerden, İpek - Sargın, FatmaDeniz. “Polycythemia vera: Update on pathogenesis, diagnosis and management.”. Journal of Istanbul Faculty of Medicine 78/3 (May. 2025): 83-91. https://doi.org/https://doi.org/10.18017/iuitfd.13056441.2015.78/3.83-91



TIMELINE



SHARE



Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.